Amicus Therapeutics Bundle
Who Owns Amicus Therapeutics?
Amicus Therapeutics is a public company with no single controlling owner. Its shares are held by public investors, institutions, and insiders, so control sits with the board and shareholders.
Founded in 2002 and public since 2007, Amicus Therapeutics shifted from founder-led roots to broad market ownership. For product context, see Amicus Therapeutics PESTEL Analysis.
Who Founded Amicus Therapeutics?
Amicus Therapeutics began with founder-led ownership, then moved into a public market structure. Today, Who owns Amicus Therapeutics comes down to a mix of common stock holders, institutional investors, insiders, and retail investors, with no publicly disclosed controlling owner.
Founder-led start
John F. Crowley was central to the early story and identity of Amicus Therapeutics. His role helped shape the company before it became a Nasdaq-listed public company.
Public ownership now
Amicus Therapeutics ownership is now spread across public shareholders, not a private sponsor or family bloc. That means ownership is based on traded shares, not a single controlling holder.
Institutional influence
Amicus Therapeutics institutional ownership is usually the most important economic block. Large holders show up in quarterly 13F filings and often shape market views of Amicus Therapeutics stockholders.
Insider presence
Amicus Therapeutics insider ownership still matters, even if it does not control the company. Founder John F. Crowley remains a visible insider and brand figure, but not a public control owner.
Governance shape
The board of directors and senior management are the main governance voices. That setup fits a widely held public company with no widely disclosed dual-class voting structure.
Why it matters
This structure can support legitimacy because no one owner can easily redirect strategy for private reasons. For investors, Amicus Therapeutics shareholder structure is best read through SEC filings and investor relations updates.
Amicus Therapeutics public float means the shares are broadly available in the market under Nasdaq: FOLD, so Amicus Therapeutics Nasdaq ownership is dispersed rather than locked inside a parent group. For a deeper look at the business context behind that ownership base, see Growth Strategy of Amicus Therapeutics.
Amicus Therapeutics ownership breakdown
Amicus Therapeutics annual report ownership and Amicus Therapeutics SEC filings ownership are the best places to verify the latest holder mix. The public record shows a company owned by many stockholders, with governance led by the board and management.
- Founder John F. Crowley shaped the early company.
- No controlling shareholder is publicly disclosed.
- No widely disclosed dual-class voting structure appears.
- Large institutions often drive ownership visibility.
Amicus Therapeutics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Amicus Therapeutics’s Ownership Changed Over Time?
Amicus Therapeutics ownership changed in three clear steps: its 2002 founding as a rare-disease venture, the 2007 IPO that moved control into public markets, and the later shift from a development story to a commercial one. That path turned John F. Crowley’s patient-led origin into a public company brand built around science, disclosure, and shareholder scrutiny.
| Ownership phase | Key shift | Brand meaning |
|---|---|---|
| 2002 founding | Founder-led, mission first | Patient-centered trust |
| 2007 IPO | Public stockholders gained influence | Broader accountability |
| Commercial stage | Institutional investors, common stock holders, and public float shaped control | Market-tested biotech profile |
Who owns Amicus Therapeutics now is best read through its Amicus Therapeutics shareholder structure: a public-company base of Amicus Therapeutics stockholders, with Amicus Therapeutics institutional ownership and Amicus Therapeutics insider ownership both reported through SEC filings and annual report ownership disclosures. For a short company timeline, see the Brief History of Amicus Therapeutics.
Ownership, trust, and market meaning
Ownership changed how the market reads Amicus Therapeutics. The founder story still matters, but public ownership now sets the rules.
- 2002 start built patient trust.
- 2007 IPO widened oversight.
- Institutional holders added discipline.
- Commercial drugs strengthened investor focus.
Amicus Therapeutics major shareholders and Amicus Therapeutics top investors now matter because public biotech is judged on capital use as much as science. That is why Amicus Therapeutics investor relations, Amicus Therapeutics board of directors, and Amicus Therapeutics SEC filings ownership all shape the brand just as much as clinical progress does.
Amicus Therapeutics ownership breakdown also helps explain why the name carries both mission and market weight. Founder influence set the tone early, but Amicus Therapeutics Nasdaq ownership now reflects a wider set of Amicus Therapeutics common stock holders, Amicus Therapeutics institutional investors list, and public-market holders who expect clear results from Galafold and Pombiliti/Opfolda.
Amicus Therapeutics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Amicus Therapeutics’s Board?
The current Amicus Therapeutics board of directors sits at the center of Amicus Therapeutics ownership and voting power. In a one-share-one-vote setup, control stays dispersed, so the board, CEO, and Amicus Therapeutics institutional ownership matter more than any single holder.
| Governance layer | What it controls | Why it matters |
|---|---|---|
| Amicus Therapeutics board of directors | Strategy, oversight, capital decisions | Sets the tone for investors and proxy votes |
| Executive management | Daily operations and execution | Shapes results that funds judge each quarter |
| Amicus Therapeutics stockholders | Elect directors and vote proposals | Large funds can sway outcomes in close votes |
Who owns Amicus Therapeutics is best answered through the Amicus Therapeutics shareholder structure, not just the share register. The public float is widely held, so Amicus Therapeutics major shareholders and Amicus Therapeutics top investors matter most when proxy season starts. Founder John F. Crowley still carries reputational weight in rare disease, and that can shape how Amicus Therapeutics investor relations is read by the market.
Who holds real influence over Amicus Therapeutics
Amicus Therapeutics board of directors, management, and institutional votes drive control. In the absence of a control fight, voting power tends to stay with coordinated funds and the board.
- One-share-one-vote limits single-owner control
- Proxy ballots matter most at annual meetings
- Institutional holders often dominate votes
- Founder influence can exceed stake size
For investors asking who are the largest shareholders of Amicus Therapeutics, the key lens is Amicus Therapeutics institutional investors list plus Amicus Therapeutics insider ownership. The latest Marketing Strategy of Amicus Therapeutics also helps explain why founder visibility and rare-disease credibility can matter as much as raw shares. Amicus Therapeutics hedge fund ownership and Amicus Therapeutics insider trading ownership may shift sentiment, but they do not create control without broad support.
Amicus Therapeutics annual report ownership and Amicus Therapeutics SEC filings ownership are the cleanest sources for exact voting stakes. For a Nasdaq ownership view, the real issue is not just Amicus Therapeutics common stock holders, but whether any large fund bloc can line up enough votes to influence director elections or say-on-pay proposals.
Amicus Therapeutics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Amicus Therapeutics’s Ownership Landscape?
Amicus Therapeutics ownership has stayed stable and public, with no shift to private control or a parent company takeover. The main trend is ordinary market turnover in Amicus Therapeutics stockholders, not a change in control, which supports credibility for investors and partners.
| Ownership layer | What it shows | Credibility signal |
|---|---|---|
| Public common stock holders | Amicus Therapeutics remains a listed biotech with a public float. | Clear disclosure and market discipline. |
| Institutional ownership | Amicus Therapeutics institutional investors list is the main ownership block. | Supports research coverage and governance checks. |
| Insider ownership | Management and directors keep a direct but non-controlling stake. | Aligns leadership with shareholders. |
Who owns Amicus Therapeutics is best answered through filings, not headlines. The Amicus Therapeutics ownership breakdown points to a standard Nasdaq structure: public float, institutional holders, and insider ownership, with no family control or leveraged buyout layer. That makes Amicus Therapeutics annual report ownership and Amicus Therapeutics SEC filings ownership more useful than any rumor when judging Amicus Therapeutics shareholder structure.
Institutional Base
Amicus Therapeutics institutional ownership helps support trading depth and analyst review. Large holders can push for tighter capital use and cleaner disclosure.
Insider Alignment
Amicus Therapeutics insider ownership gives management some skin in the game. That matters when execution pressure is high and market patience is low.
Governance Clarity
The Amicus Therapeutics board of directors remains a visible control point through proxy voting and SEC filings. That openness is a plus for credibility and investor relations.
Market Discipline
Because Amicus Therapeutics is not privately controlled, price moves and shareholder votes can pressure the team fast. You can see this same public-market setup in the Competitors Landscape of Amicus Therapeutics.
Amicus Therapeutics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Brief History of Amicus Therapeutics Company?
- What is Competitive Landscape of Amicus Therapeutics Company?
- What is Growth Strategy and Future Prospects of Amicus Therapeutics Company?
- How Does Amicus Therapeutics Company Work?
- What is Sales and Marketing Strategy of Amicus Therapeutics Company?
- What are Mission Vision & Core Values of Amicus Therapeutics Company?
- What is Customer Demographics and Target Market of Amicus Therapeutics Company?
Frequently Asked Questions
Amicus Therapeutics is publicly owned, so no single person or parent controls it. The company was founded in 2002, went public in 2007, and trades on Nasdaq under FOLD. Its owners are a mix of institutions, insiders, and retail shareholders, with exact percentages shifting each quarter in proxy and 13F filings.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.